Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
4.0
4.2
Journals
Biology
Special Issues
Medicinal Plants and Natural Products in the Management of Cancers
share announcement

Medicinal Plants and Natural Products in the Management of Cancers

A special issue of Biology (ISSN 2079-7737). This special issue belongs to the section "Medical Biology".

Deadline for manuscript submissions: closed (28 February 2022) | Viewed by 9499

Special Issue Editors

Dr. Elena Andreucci

E-Mail Website
Guest Editor
Department of Clinical and Experimental Biomedical Sciences “Mario Serio”, Section of Experimental Pathology and Oncology, University of Florence, V. le Morgagni, 50, 50134 Florence, Italy
Interests: tumor microenvironment; extracellular acidosis; tumor angiogenesis; tumor-derived extracellular vescicles (exososmes-ectososmes); cancer metabolism
Special Issues, Collections and Topics in MDPI journals
Dr. Jessica Ruzzolini

E-Mail Website
Guest Editor
Department of Experimental and Clinical Biomedical Sciences “Mario Serio”, University of Florence, Florence, Italy
Interests: cancer development and metastasis; tumor microenvironment; cell metabolism; inflammation; complementary therapy; nutraceutics
Dr. Silvia Peppicelli

E-Mail Website
Guest Editor
Department of Experimental and Clinical Biomedical Sciences “Mario Serio”, University of Florence, 50134 Florence, Italy
Interests: tumor microenvironment; melanoma progression; cancer stem cells; tumor acidosis; tumor metabolism
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Cancer treatment is now mainly based on combinatory therapeutic strategies to overcome the limitations encountered with single agent-based therapies. An emerging field in cancer research is dedicated to the use of nutraceuticals in complementary therapies because of the several beneficial effects they exhibit. Indeed, in recent years, a larger amount evidence has been collected on the effects of natural products on cancer management, in terms of increasing therapy response and reducing cytotoxic side effects caused by chemotherapy, one of the biggest limitations of cancer treatment.

Thus, because of the potential applicability in the clinic, this hot topic deserves an even higher amount of interest within the scientific community. Researchers’ efforts in this field could in the very near future become a concrete possibility for cancer patients to complement the therapeutic protocols with natural products as food supplements, able to strengthen antitumoral response, ameliorating disease prognosis and patients’ outcome.

For this reason, this Special Issue welcomes the submission of original research and review manuscripts focusing on the effects of medicinal plants and natural products in cancer management, with a particular—but not restricted—interest in elucidating the mechanisms by which they synergize with antitumor therapy and prevent cytotoxic side effects in cancer patients.

Dr. Elena Andreucci
Dr. Jessica Ruzzolini
Dr. Silvia Peppicelli
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biology is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • medicinal plants
  • natural products
  • nutraceutics
  • cancer treatment
  • complementary therapy
  • drug resistance
  • tumor progression
  • chemotherapy-induced side effects
  • tumor angiogenesis
  • tumor inflammation

Published Papers (1 paper)

Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Review

25 pages, 1380 KiB  
Review
Vincristine in Combination Therapy of Cancer: Emerging Trends in Clinics
by Jan Škubník, Vladimíra Svobodová Pavlíčková, Tomáš Ruml and Silvie Rimpelová
Biology 2021, 10(9), 849; https://doi.org/10.3390/biology10090849 - 31 Aug 2021
Cited by 43 | Viewed by 8604
Abstract
Treatment of blood malignancies and other cancer diseases has been mostly unfeasible, so far. Therefore, novel treatment regimens should be developed and the currently used ones should be further elaborated. A stable component in various cancer treatment regimens consists of vincristine, an antimitotic [...] Read more.
Treatment of blood malignancies and other cancer diseases has been mostly unfeasible, so far. Therefore, novel treatment regimens should be developed and the currently used ones should be further elaborated. A stable component in various cancer treatment regimens consists of vincristine, an antimitotic compound of natural origin. Despite its strong anticancer activity, mostly, it cannot be administered as monotherapy due to its unspecific action and severe side effects. However, vincristine is suitable for combination therapy. Multidrug treatment regimens including vincristine are standardly applied in the therapy of non-Hodgkin lymphoma and other malignancies, in which it is combined with drugs of different mechanisms of action, mainly with DNA-interacting compounds (for example cyclophosphamide), or drugs interfering with DNA synthesis (for example methotrexate). Besides, co-administration of vincristine with monoclonal antibodies has also emerged, the typical example of which is the anti-CD20 antibody rituximab. Although in some combination anticancer therapies, vincristine has been replaced with other drugs exhibiting lesser side effects, though, in most cases, it is still irreplaceable. This is strongly evidenced by the number of active clinical trials evaluating vincristine in combination cancer therapy. Therefore, in this article, we have reviewed the most common cancer treatment regimens employing vincristine and bring an overview of current trends in the clinical development of this compound. Full article
(This article belongs to the Special Issue Medicinal Plants and Natural Products in the Management of Cancers)
►▼ Show Figures

Graphical abstract

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-1
Back to TopTop